Antibody-Drug Conjugate Targeting GRP94 for Cancer Treatment
Summary
The USPTO published patent application US20260097129A1 for an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 (glucose-regulated protein 94) or an antigen-binding fragment thereof. The invention includes a pharmaceutical composition for treating cancer, leveraging strong internalization activity against GRP94-overexpressed carcinomas. The conjugate effectively inhibits growth of cetuximab-resistant colorectal cancer cell lines including HT29, HCT116, HCT8, and LoVo cells.
What changed
The USPTO published patent application US20260097129A1 disclosing an antibody-drug conjugate (ADC) comprising a cytotoxic agent conjugated to an antibody specifically targeting GRP94 with strong internalization activity. The invention covers pharmaceutical compositions for treating various carcinomas where GRP94 is overexpressed, demonstrating efficacy against cetuximab-resistant colorectal cancer cell lines.
For pharmaceutical and biotechnology companies developing cancer therapeutics, this patent represents potential prior art for ADC development targeting heat shock proteins or GRP94. Freedom-to-operate analyses should consider this application when developing similar conjugate technologies. The claimed invention's focus on overcoming EGFR antibody resistance may influence R&D strategies in targeted oncology.
What to do next
- Monitor for patent grant status
- Review patent claims for freedom-to-operate analysis
- Assess licensing opportunities if applicable
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTIBODY-DRUG CONJUGATE COMPRISING DRUG AND ANTIBODY SPECIFICALLY BINDING TO GRP94 OR ANTIGEN-BINDING FRAGMENT THEREOF
Application US20260097129A1 Kind: A1 Apr 09, 2026
Inventors
Sukmook LEE, Yea Bin CHO, Ji Woong KIM, Kyun HEO, Hyun Jung KIM
Abstract
The present invention relates to: an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 or an antigen-binding fragment thereof; and a pharmaceutical composition for treating cancer, comprising same as an active ingredient. The antibody-drug conjugate of the present invention comprises an antibody specifically targeting GRP94 and having strong internalization activity, and, as a result of conjugation with a cytotoxic agent, effectively inhibits the growth of cetuximab-resistant CRC cell lines including HT29, HCT116, HCT8 and LoVo cells, and thus can be effectively used as a therapeutic agent for various carcinomas in which GRP94 is overexpressed.
CPC Classifications
A61K 47/68033 A61K 47/6843 A61P 35/04 C07K 16/18 C12N 15/85
Filing Date
2023-09-25
Application No.
19114039
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.